The global dry eye syndrome treatment market size is expected to reach US$ 4.80 billion in 2022 and increase at a robust 7.0% CAGR between 2022 and 2032, attaining a valuation of US$ 9.44 billion by the end of 2032.
The increased prevalence of dry eye syndrome, combined with rising demand for dry eye treatment to alleviate various symptoms, is a primary driver driving the dry eye syndrome treatment market’s rise.
Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1215
Dry eye disease (DED) has emerged as a public health issue, producing ocular discomfort, weariness, and visual disruption that impairs quality of life. It is one of the most prevalent and distressing ocular surface disorders (OSDs).
It occurs when tears are unable to supply adequate moisture/lubrication or when tears are produced insufficiently. This disorder can cause a variety of symptoms, including redness of the eyes, a burning feeling, and inflammation, as well as itching and poor vision.
Key Takeaways:
- The US accounted for 80.6% of the North American dry eye syndrome treatment market in 2022.
- In 2022, Germany held about 17.2% of the dry eye syndrome treatment market share in Europe.
- Based on the product type, the artificial tears category will expand at a 7.1% CAGR.
- By distribution channel, the hospital pharmacies will continue to dominate the market in the assessment period.
Competitive Landscape
In a competitive environment, prominent market players are focusing on increasing research and development efforts to develop new products with long-lasting attributes and greater efficiency. These organizations vigorously engage in product launches, agreements, and approvals to enhance their market footprints. In the recent timeline, that is between 2019 and 2021, many businesses have actively sought product approval and concentrated on releasing novel products. For instance, in October 2021, Tyrvaya nasal spray for dry eye was approved by the US Food and Drug Administration (FDA). Other developments include the October 2019 announcement of Sun Pharmaceutical Industries Ltd., that one of its subsidiaries had commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the US.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1215
Key Players:
Allergen plc. (Abbvie), Novartis AG, Otsuka Pharmaceuticals Co., Ltd., Bausch Health Companies, Inc. Akron, Inc., Johnson & Johnson, Inc., Thea Pharmaceuticals Limited, OASIS Medical, Altaire Pharmaceuticals Inc., Boiron USA, Similasan Corporation, Scope Ophthalmics Ltd., Reckitt Benckiser Group PLC, Medicom Healthcare Ltd, FDC Limited., Lupin Limited, Jamjoom Pharmaceuticals Co., and Sentiss Pharma Private limited
More Insights Into Dry Eye Syndrome Treatment Market
For a comprehensive understanding of the global market potential, growth, and scope, the market is segmented on the basis of product type, prescription, distribution channel, and region. According to the same reports, based on segmentation, the Rx (prescription) medicine category held about 71.4% of the overall market share in 2021. In terms of distribution channels, the retail and hospital pharmacies segment will lead the market growth. Based on region, the dry eye syndrome treatment market in the US, Germany, and China will present impressive growth during the forecast period.
In this latest report, FMI offers a detailed and unbiased analysis of the global dry eye syndrome treatment market, providing historical data from 2016 to 2021 and forecast statistics for 2022 to 2032. The report highlights include a 9-year realistic sales prediction for the market, demand and supply trend analysis, illustrative representation of statistical data, and strategies adopted by leading players to retain a competitive edge.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-1215
Dry Eye Syndrome Treatment Market By Category
By Product:
- Cyclosporine
- Topical Corticosteroids
- Artificial Tears
- Punctal Plugs
- Removable
- Dissolvable
- Oral Omega Supplements
- Others
By Prescription:
- Rx
- OTC
- Medical Device
By Distribution Channel:
- Hospital Pharmacies
- Eye Health Clinics
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
